Roche breast cancer drug 'unprecedented' in extending lives<p><a href="http://news.yahoo.com/roche-breast-cancer-drug-shows-unprecedented-survival-benefit-071501068--finance.html"><img src="http://l3.yimg.com/bt/api/res/1.2/13mT5Z4.EJ.GU6wO9matgw--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9Njk7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2014-09-28T071501Z_1_LYNXNPEA8R06R_RTROPTP_2_ROCHE-CHINA-FRAUD.JPG" width="130" height="86" alt="The logo of Swiss pharmaceutical company Roche is seen outside the Shanghai Roche Pharmaceutical Co. Ltd. headquarters in Shanghai" align="left" title="The logo of Swiss pharmaceutical company Roche is seen outside the Shanghai Roche Pharmaceutical Co. Ltd. headquarters in Shanghai" border="0" /></a>By Ben Hirschler MADRID (Reuters) - A new breast cancer drug from Roche has shown "unprecedented" benefits in extending lives in a clinical trial and experts urged its widespread use for women with an aggressive form of the disease. Patients with a type of breast cancer known as HER2 positive, which makes up about a quarter of all breast cancers, who were given Perjeta on top of older medicine Herceptin and chemotherapy lived 15.7 months longer than those on Herceptin and chemotherapy alone. ...</p><br clear="all"/>
Source: Roche breast cancer drug 'unprecedented' in extending lives (http://news.yahoo.com/roche-breast-cancer-drug-shows-unprecedented-survival-benefit-071501068--finance.html)